Replies to post #108941 on Avid Bioservices Inc (CDMO)

[freethemice]

Andy, I agree with his estimate. If the gemcitabine control arm has a MOS of about 6.5 months then a
MOS of 11.5 months for the bavi + gem arm would be a new record for increased number of months and
percentage increase. It still might not be statistically significant due to the small number of patients in
each arm, but it should get the go ahead for a phase 3 trial.